4D Molecular Therapeutics (FDMT) Net Margin: 2020-2025
Historic Net Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -63,195.56%.
- 4D Molecular Therapeutics' Net Margin rose 139823778.00% to -63,195.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -174,314.17%, marking a year-over-year increase of 66968583.00%. This contributed to the annual value of -434,778.38% for FY2024, which is 43429178.00% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Net Margin stood at -63,195.56% for Q3 2025, which was up 82.66% from -364,386.67% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Net Margin ranged from a high of 169,910.53% in Q4 2023 and a low of -4,967,100.00% during Q4 2024.
- In the last 3 years, 4D Molecular Therapeutics' Net Margin had a median value of -115,717.86% in 2024 and averaged -715,064.30%.
- Per our database at Business Quant, 4D Molecular Therapeutics' Net Margin plummeted by 513,701,053bps in 2024 and then soared by 139,823,778bps in 2025.
- 4D Molecular Therapeutics' Net Margin (Quarterly) stood at -27,264.13% in 2021, then skyrocketed by 2,506,854bps to -2,195.59% in 2022, then skyrocketed by 17,210,612bps to 169,910.53% in 2023, then crashed by 513,701,053bps to -4,967,100.00% in 2024, then surged by 139,823,778bps to -63,195.56% in 2025.
- Its Net Margin stands at -63,195.56% for Q3 2025, versus -364,386.67% for Q2 2025 and -342,657.14% for Q1 2025.